美通社

2024-09-24 20:00

Eyebright Medical Continues to Employ Its Internationalization Strategy: Signed Memorandum with Invest Hong Kong and Spotlight at ESCRS 2024

HONG KONG, Sept. 24, 2024 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is pleased to announce the recently development of its internationalization strategy.

Eyebright Medical has signed a memorandum of cooperation with the Invest Hong Kong, Leverages Hong Kong as a Platform for Global Expansion

On September 20, Eyebright Medical was invited to the opening ceremony of the 27th Beijing-Hong Kong Economic Cooperation Forum and Investment Promotion Conference.

During the signing ceremony for key projects between Beijing and Hong Kong, Eyebright Medical signed a memorandum of cooperation with the Invest Hong Kong of the Hong Kong Special Administrative Region government.

Eyebright Medical aims to utilize Hong Kong as a platform for its international outreach, establishing it as a base for expanding overseas operations. Invest Hong Kong will provide essential information on the business environment and government policies, along with a suite of support services, including talent acquisition, financing options, and government funding programs.


Shines on the ESCRS 2024 and Showcasing the Leading R&D Capabilities to the World

From September 6 to 10, 2024, Eyebright Medical has participated in the 42nd European Society of Cataract and Refractive Surgeons Congress (ESCRS) showcased its range of self-developed products in cataract surgery, myopia management, and consumer vision care, receiving significant recognition in the global market and reinforcing its commitment to excellence in ophthalmic care. The grand event had attracted over 15,000 participants and facilitating valuable exchanges among leading ophthalmic experts.

Eyebright Medical's star products, including the monofocal EDOF intraocular lens, multifocal EDOF intraocular lens, and preloaded high-order aspheric intraocular lens series, garnered significant attention at the ESCRS Congress, attracting agents and doctors from around the world eager to learn about and experience these cutting-edge innovations.

The monofocal EDOF lens enhances postoperative intermediate and near vision while minimizing visual disturbances, whereas the multifocal EDOF lens offers clear distance and near vision alongside functional intermediate vision, reducing adverse visual phenomena. Additionally, the preloaded intraocular lens features a streamlined one-step operation design that greatly improves surgical efficiency and safety. With corresponding Toric versions available, Eyebright Medical's high-end intraocular lens series effectively meets the personalized selection needs for refractive cataract surgery.


ESCRS has always been an excellent opportunity to share the latest advancements in the field of ophthalmology, learn about innovative products, and connect with peers from around the world. This time, Eyebright Medical showcased its full range of self-developed products at ESCRS, gaining increased attention and recognition in the overseas market. Furthermore, it facilitated in-depth exchanges with international experts and scholars in the field of ophthalmology, discussing cutting-edge technologies and development directions, injecting new momentum into its progress toward becoming a leading international medical enterprise.

About Eyebright Medical
Eyebright Meical Technology (Beijing) Ltd ("Eyebright Medical"; SH Stock Code: 688050.SH) is a National High-tech Enterprise and state-level technologically advanced 'little giant' enterprises, located in Zhongguancun Science and Technology Park, Beijing, China.

The Company is an innovation-driven ophthalmic medical device manufacturer. Its balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Anchored by its three core product categories - intraocular lenses, orthokeratology lenses, and soft contact lenses - the company has strategically expanded its product pipeline to cover the full life cycle of eye health solutions. Eyebright Medical is striding into a world-leading medical enterprise on behalf of China's 'intelligent manufacturing' power.

For more information about Eyebright Medical, please visit the official website of the Group: http://www.ebmedical.com/en/.

source: Eyebright Medical Technology (Beijing) Co., Ltd.

【立即投票】今個農曆新年你會如何度過? ► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
5
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
6
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
7
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
8
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
9
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
10
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
11
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
12
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
13
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
14
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
15
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
16
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
17
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
18
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
19
去旅行 | 攜程:首十一月香港用戶平均出境航班次數增至1.9次
20
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
21
港股 | 蕭猷華:恒指春節前可挑戰21500點
22
港股 | 蕭猷華:恒指春節前目標21500點
23
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
24
一本萬利 | 2025年的五個「勿」(有片)
25
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
26
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
27
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
28
微盟 | 炒完微信小店,微盟(2013)遭三名主要股東急沽持股套現
29
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
30
習近平應約與特朗普通電話,特:冀盡快與習見面
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老